Regeneron Gets US Patent for Radiolabeled Anti-MET Antibodies
Summary
The USPTO granted Regeneron Pharmaceuticals, Inc. Patent US12605473B2 covering radiolabeled anti-MET antibodies and MET×MET bispecific antibodies for immuno-PET imaging. The patent includes 28 claims and covers methods of detecting MET proteins in subjects or samples and methods of monitoring treatment efficacy in MET-expressing tumors. The patent application was filed December 29, 2023.
About this source
GovPing monitors USPTO Patent Grants - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 190 changes logged to date.
What changed
USPTO granted Regeneron Pharmaceuticals, Inc. Patent US12605473B2 on April 21, 2026, covering radiolabeled anti-MET binding proteins and their use in immuno-PET imaging. The patent claims radiolabeled anti-MET antibodies and bispecific antibodies, as well as methods of detecting MET proteins and monitoring efficacy of treatment in MET-expressing tumors.
For Regeneron and other pharmaceutical companies working in targeted oncology imaging, this patent establishes intellectual property protection around MET-targeted radiopharmaceutical compositions. Parties developing similar radiolabeled antibody products for immuno-PET applications may need to evaluate potential infringement risks or consider licensing discussions with Regeneron.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods for making radiolabeled anti-MET binding proteins
Grant US12605473B2 Kind: B2 Apr 21, 2026
Assignee
REGENERON PHARMACEUTICALS, INC.
Inventors
Marcus Kelly, Dangshe Ma, William Olson
Abstract
Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.
CPC Classifications
A61K 51/103 A61K 51/1093 C07K 16/2863 C07K 2317/21 C07K 2317/31 C07K 2317/565 C07K 2317/77 C07K 2317/92 C07K 2317/94 G01N 2333/71 G01N 33/534 A61P 35/00
Filing Date
2023-12-29
Application No.
18400943
Claims
28
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.